Contrast Media & Molecular Imaging

Molecular Imaging: In Vivo Agents for the Diagnosis and Treatment of Cancer


Publishing date
01 Aug 2018
Status
Published
Submission deadline
30 Mar 2018

1WISIA-Women in Science-an InterdisciplinaryAssociation, Vienna, Austria

2Medical University of Innsbruck, Innsbruck, Austria

3Johns Hopkins University, Baltimore, USA

4Virginia Commonwealth University, Virginia, USA

5National Taiwan University Hospital, Taipei, Taiwan


Molecular Imaging: In Vivo Agents for the Diagnosis and Treatment of Cancer

Description

As stated by the WHO, cancer is the second leading cause of death globally, leading to the fact that 1 in 6 deaths is due to cancer. Additionally, the economic impact of cancer is both significant and increasing; hence, visualization as well as effective tailored treatment is crucial and becomes more and more important nowadays. Moreover, early detection of primary tumors, as well as potential metastases, has a significant impact on the therapy regime and overall survival rates of patients. Therefore, both clinician and patient would benefit highly from appropriate (imaging) agents.

As prerequisites, different molecular imaging modalities (PET, SPECT, CT, MRI, ultrasound, and nanoparticles) and corresponding agents have been developed or are in development for the combat against cancer. For example, highly sensitive and specific in vivo agents allow for the visualization of receptor systems, enzymes, and proteins involved in cancer biochemistry and/or pathophysiology. Furthermore, the development of tracers for the characterization of the vast heterogeneity of cell types within a tumor and its microenvironment (stromal cells, endothelial cells, immune cells, etc.) is and will be of great value to tackle some of the so far unanswered questions regarding cancer and its mechanisms.

Although there is evidence for ongoing progress in these fields, one has to admit that research is it still in its infancy. Hence, it is the aim of this special issue to encourage high quality work contributing to these important topics.

Potential topics include but are not limited to the following:

  • PET- and SPECT-tracers as specific targets for the clinical visualization and treatment of cancer, cancer cells, and the tumor microenvironment
  • MRI agents for the in vivo detection of malignancies
  • Imaging agents for the early diagnosis of tumors and metastases
  • Emerging tracers for the treatment of cancer
  • Nanoparticles for the imaging and treatment of cancer and cell related cancer processes
  • Diagnostic, therapeutic, and theranostic in vivo agents with direct clinical application
  • Imaging biomarkers for colon, mamma, and prostate carcinoma and melanoma
  • Recent advances in preclinical and clinical application of in vivo biomarkers of cancer mechanisms or cancer cells
  • Macromolecules for the imaging of cancer and malignant processes

Articles

  • Special Issue
  • - Volume 2018
  • - Article ID 8541915
  • - Editorial

Molecular Imaging: In Vivo Agents for the Diagnosis and Treatment of Cancer

D. Haeusler | C. Decristoforo | ... | Y. Y. Huang
  • Special Issue
  • - Volume 2018
  • - Article ID 8425495
  • - Research Article

InVivo Molecular Ultrasound Assessment of Glioblastoma Neovasculature with Endoglin-Targeted Microbubbles

Cheng Liu | Fei Yan | ... | Lei Sun
  • Special Issue
  • - Volume 2018
  • - Article ID 2015237
  • - Review Article

Targeted Optical Imaging Agents in Cancer: Focus on Clinical Applications

Bishnu P. Joshi | Thomas D. Wang
  • Special Issue
  • - Volume 2018
  • - Article ID 3215658
  • - Research Article

Measuring Tumor Metabolism in Pediatric Diffuse Intrinsic Pontine Glioma Using Hyperpolarized Carbon-13 MR Metabolic Imaging

Adam W. Autry | Rintaro Hashizume | ... | Ilwoo Park
  • Special Issue
  • - Volume 2018
  • - Article ID 6930425
  • - Research Article

Comparative Evaluation of Radioiodine and Technetium-Labeled DARPin 9_29 for Radionuclide Molecular Imaging of HER2 Expression in Malignant Tumors

Anzhelika Vorobyeva | Olga Bragina | ... | Sergey Deyev
  • Special Issue
  • - Volume 2018
  • - Article ID 7832805
  • - Research Article

Evaluation of 99mTc-HYNIC-VCAM-1scFv as a Potential Qualitative and Semiquantitative Probe Targeting Various Tumors

Xiao Zhang | Fan Hu | ... | Xiaoli Lan
  • Special Issue
  • - Volume 2018
  • - Article ID 2023604
  • - Research Article

Thallium Labeled Citrate-Coated Prussian Blue Nanoparticles as Potential Imaging Agent

Krisztián Szigeti | Nikolett Hegedűs | ... | Domokos Máthé
  • Special Issue
  • - Volume 2018
  • - Article ID 3171794
  • - Research Article

Exploiting the Concept of Multivalency with 68Ga- and 89Zr-Labelled Fusarinine C-Minigastrin Bioconjugates for Targeting CCK2R Expression

Dominik Summer | Christine Rangger | ... | Clemens Decristoforo
  • Special Issue
  • - Volume 2018
  • - Article ID 2461257
  • - Research Article

Tumor-Shed Antigen Affects Antibody Tumor Targeting: Comparison of Two 89Zr-Labeled Antibodies Directed against Shed or Nonshed Antigens

Jae-Ho Lee | Heejung Kim | ... | Chang H. Paik
  • Special Issue
  • - Volume 2018
  • - Article ID 7929617
  • - Research Article

Construction and Evaluation of the Tumor-Targeting, Cell-Penetrating Multifunctional Molecular Probe iCREKA

Li-juan Wang | Hong-sheng Li | ... | Shun Huang
Contrast Media & Molecular Imaging
Publishing Collaboration
More info
Wiley Hindawi logo
 Journal metrics
Acceptance rate58%
Submission to final decision65 days
Acceptance to publication40 days
CiteScore3.200
Impact Factor1.984
 Submit

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.